Zevra Therapeutics
Neil McFarlane has a diverse work experience. Neil is currently serving as the Chief Executive Officer at Zevra Therapeutics since September 2023. Prior to that, they worked as a Board Member at Collegium Pharmaceutical, Inc. in 2022. From 2019 to 2021, they held the position of Chief Executive Officer at Adamas Pharmaceuticals, Inc. Before that, they served as the Chief Operating Officer at Travere Therapeutics from 2016 to 2019. Neil McFarlane has also worked in various leadership roles at UCB between 2011 and 2016, including Vice President, Global and Vice President & General Manager, U.S. Additionally, they have experience as a Managing Director at Inlet Partners from 2009 to 2011. In the earlier years of their career, they worked at Sanofi Genzyme in roles such as Vice President, International, Vice President, Europe, and Director. Prior to that, they served in the United States Army Reserve from 1989 to 2005. Neil also worked as a Director at SANGSTAT MEDICAL CORP from 2000 to 2003.
Neil McFarlane has attended the University of Florida, where they did not complete a degree or specific field of study. Neil has also participated in the Harvard Business School Executive Education program, completing a finance course designed for senior executives. Additionally, they have attended the University of Miami, but did not obtain a degree or specialize in any particular field of study.
This person is not in any offices
Zevra Therapeutics
1 followers
We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients’ lives.